Creative Medical Technology Holdings (CELZ) Cash from Financing Activities (2010 - 2026)
Creative Medical Technology Holdings (CELZ) posted quarterly Cash from Financing Activities of $13360.0 for Q1 2026, down 99.6% year-over-year from $3.4 million in Q1 2025, and down 99.65% quarter-over-quarter from $3.8 million in Q4 2025.
Creative Medical Technology Holdings (CELZ) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Creative Medical Technology Holdings (CELZ) has reported Cash from Financing Activities for 17 consecutive years, with $13360.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Financing Activities fell 99.6% year-over-year to $13360.0; the TTM figure through Mar 2026 stood at $3.8 million (down 21.62% YoY), while the FY2025 annual figure was $7.2 million, up 393.23% from the prior year.
- Cash from Financing Activities retreated to $13360.0 in Q1 2026 per CELZ's latest filing, from $3.8 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $15.5 million in Q2 2022 and bottomed at -$191780.0 in Q3 2023.
- Historically, Cash from Financing Activities has averaged $2.2 million across 5 years, with a median of $12.0 in 2022.
- Annual changes were most pronounced in 2022 — Cash from Financing Activities jumped 14552.69% — and 2023, when it tumbled 1598266.67%.
- Creative Medical Technology Holdings' Cash from Financing Activities stood at $12.0 in 2022, then slumped by 659866.67% to -$79172.0 in 2023, then surged by 2158.18% to $1.6 million in 2024, then surged by 134.47% to $3.8 million in 2025, then tumbled by 99.65% to $13360.0 in 2026.
- Business Quant data shows CELZ's Cash from Financing Activities at $13360.0 in Q1 2026, $3.8 million in Q4 2025, and $3.4 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Creative Medical Technology Holdings | 1.88 Mn | 1.88 Mn | - | 4.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.46 Mn |
| Jun 30, 2026 | 4.46 Mn |
| Mar 31, 2026 | 13,360.00 |
| Mar 31, 2026 | 13,360.00 |
| Dec 31, 2025 | 3.82 Mn |
| Dec 31, 2025 | 3.82 Mn |
| Mar 31, 2025 | 3.35 Mn |
| Mar 31, 2025 | 3.35 Mn |
| Dec 31, 2024 | 1.63 Mn |
| Dec 31, 2024 | 1.63 Mn |
| Sep 30, 2024 | -25,450.00 |
| Sep 30, 2024 | -25,450.00 |
| Jun 30, 2024 | -66,618.00 |
| Jun 30, 2024 | -66,618.00 |
| Mar 31, 2024 | -82,796.00 |
| Mar 31, 2024 | -82,796.00 |
| Dec 31, 2023 | -79,172.00 |
| Dec 31, 2023 | -79,172.00 |
| Sep 30, 2023 | -191,780.00 |
| Sep 30, 2023 | -191,780.00 |